An observational study in Sepsis, Long Term Care and Sepsis Scores, sponsored by University of Geneva, Switzerland. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by University of Geneva, Switzerland · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Sepsis with a site in Switzerland — 9 open to participants now, 9 under way, 1 of them phase 3. Sepsis · Switzerland.
Among the 49 studies in Sepsis with a site in Switzerland, this one is the 7th largest by planned enrollment of the 23 observational ones that give a count, is one of 3 that started in 2026, is one of 24 observational ones, and was the 49th registered.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →9 of the 49 studies in Sepsis with a site in Switzerland are open now. Recruiting first, the newest first:
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18+
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 18+
Angela HUTTNER · Sites in Switzerland
Ages 18+
Hannover Medical School · Sites in Switzerland, Austria, Germany
Ages 18–80
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 530 is above the median of 150 across 1,166 observational studies indexed under Sepsis.
Median enrollment 253 across the 24 interventional studies, 82 across the 23 observational. Of the 35 that completed or were terminated, 4 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 49 have an industry lead sponsor. The 10 most frequent:
University of Geneva, Switzerland is the lead sponsor of 43 studies on the registry; 15 are open to participants now.
University of Geneva, Switzerland has 1 study filed under Sepsis — fewer than ten, so there is no comparison to draw.
5 of the studies in Sepsis with a site in Switzerland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07063095Phase 3Angela HUTTNERA Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections | 2026-12 |
| NCT03643367University of ZurichSevoflurane Sedation in Patients With Septic Shock | 2027-02 |
| NCT05647096Santersus AGSafety, Tolerability and Performance of the NucleoCapture Device in the Reduction of Circulating CfDNA/NETs in Subjects with Sepsis | 2027-05-05 |
| NCT07597122Insel Gruppe AG, University Hospital BernMIRNA QUANTIFICATION IN PATIENTS WITH SEPTIC SHOCK | 2027-05-31 |
| NCT07863128University of Geneva, SwitzerlandLong-Term Recovery and Quality of Life in Sepsis Survivors | 2027-09-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 49 studies in Sepsis with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn about the long-term outcomes and recovery of adult patients admitted to the intensive care unit (ICU) with sepsis.
The main questions it aims to answer are:
This is an international, multicentre, prospective observational cohort study. It will consecutively enrol adult patients (18 years or older) admitted to participating ICUs with sepsis, diagnosed by the treating clinician at ICU admission and, where locally available, meeting Sepsis-3 criteria.
Participants will:
The study plans to enrol 600 patients in participating ICUs across several countries, coordinated by Geneva University Hospitals (HUG).
Findings will help identify modifiable factors that may improve long-term recovery and guide future interventions for sepsis survivors.
Sepsis is a leading cause of death and long-term disability worldwide. Survivors often experience persistent physical, psychological and cognitive impairments, described as Post-Sepsis Syndrome in addition to Post-Intensive Care Syndrome (PICS). Despite growing recognition of these complications, the factors influencing long-term outcomes - particularly the interaction between individual characteristics, infection-related factors and centre-level practices - remain poorly understood.
UNCOVER is a prospective, international, multicentre observational cohort study designed to investigate these associations in adult ICU patients with sepsis. Geneva University Hospitals (HUG) acts as the promoter. Participating centres enrol patients consecutively; each centre targets 30 consecutive patients during a six-month enrolment period, and enrolment stops once 600 participants have been included. Additional participating ICUs in Europe, the Americas, Asia-Pacific, the Middle East and Africa will be added to this record as local ethics approvals are obtained.
Data are collected from medical records at ICU admission, on day 7 and at ICU discharge, and at follow-up 28 days, 3 months and 6 months after ICU admission. Collected variables include:
Because patients with sepsis are in an emergency situation and frequently lack decision-making capacity (altered consciousness, sedation, intubation), immediate inclusion with deferred consent is used, in accordance with articles 30 and 31 of the Swiss Human Research Act: advance directives are consulted, an independent physician not involved in the research safeguards the patient's interests, proxy consent is obtained from the legal representative or next of kin as soon as possible, and consent is requested from the patient post hoc as soon as capacity is recovered.
The primary outcome is health-related quality of life measured with the EQ-5D-5L at 6 months; poor quality of life is defined a priori as an EQ-5D-5L index value below 0.6. Secondary outcomes include 6-month mortality, broader quality of life (SF-12), cognitive function (T-MoCA), post-traumatic stress symptoms (IES-R), functional status (Barthel Index, extended Barthel, IADL), frailty (Clinical Frailty Scale), return to work and socio-economic recovery, rehospitalisation and healthcare utilisation, and patient-reported decision regret and preferences regarding future ICU admission.
Pre-specified secondary analyses will examine the association between long-term patient-centred outcomes and: sepsis-related delirium during the ICU stay; duration of antibiotic therapy (7 days or less versus more than 7 days); time to adequate antibiotic therapy; hospital-acquired versus community-acquired sepsis; immunosuppression; hyperoxia exposure during the ICU stay; and clinical parameters before initiation of renal replacement therapy as predictors of renal recovery and associated long-term quality of life.
The primary analysis uses a hierarchical logistic regression model with centre as a random intercept, with predictors at centre level (country), patient level (Clinical Frailty Scale, Charlson Comorbidity Index, SOFA) and infection level (time to adequate antibiotic therapy, source control achieved). Six-month mortality is analysed with a shared-frailty Cox model with centre as the frailty term. Analyses are performed in R (version 4.3 or higher) and STATA 16.1.
No experimental intervention is administered; all treatments follow local standard of care and remain the responsibility of the attending medical team. Data are coded at source and entered into a secure REDCap registry hosted by the Swiss Society of Intensive Care Medicine (SGI/SSMI).
The study is supported by a EUR 20,000 grant from the European Society of Intensive Care Medicine (ESICM), which has no role in the design, conduct, data collection, analysis, interpretation or decision to publish.
Adult patients (18 years or older) consecutively admitted to participating ICUs with community- or hospital-acquired sepsis diagnosed by the treating clinician at ICU admission and, where locally available, meeting Sepsis-3 criteria. Participating ICUs are academic and non-academic centres in several countries. Participants represent a broad spectrum of disease severity, comorbidity and infection source. Sepsis acquired in the ICU and patients admitted for palliative care are not included. No experimental intervention is administered; all treatments follow local standard of care. Because sepsis is an emergency condition and patients frequently lack decision-making capacity at the time of ICU admission, patients are included immediately and consent is obtained from a legal representative or next of kin as soon as possible and from the patient post hoc once capacity is recovered, in accordance with articles 30 and 31 of the Swiss Human Research Act.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This cohort includes adult patients (≥18 years) admitted to participating intensive care units (ICUs) with a diagnosis of sepsis according to SEPSIS-3 criteria. Participants will be followed prospectively at 28 days, 3 months, and 6 months after ICU admission to assess patient-centered outcomes including quality of life, functional recovery, cognitive status, and mental health. No experimental interventions will be administered; all treatments follow standard clinical practice. Data on infection characteristics, antibiotic timing, and ICU management will be recorded for association analyses.
Other: Care for Sepsis
Participants will receive standard clinical care for sepsis according to local hospital protocols. This study is purely observational: no experimental drugs, procedures, or behavioral interventions are introduced. Data will be collected prospectively on infection characteristics, timing of adequate antibiotic therapy, organ support, and rehabilitation practices during the ICU stay. Follow-up at 28 days, 3 months, and 6 months will assess patient-centered outcomes such as quality of life (EQ-5D-5L), cognitive and mental health status, and return to work. All treatments and decisions remain under the responsibility of the attending medical team.
Health-related Quality of Life
Health-related quality of life measured with the EQ-5D-5L. The EQ-5D-5L index value ranges approximately from below 0 to 1, with higher values indicating better health-related quality of life. Poor quality of life is defined a priori as an index value below 0.6.
Time frame: 6 months after ICU admission
Health-related Quality of Life
Health-related quality of life measured with the EQ-5D-5L. The EQ-5D-5L index value ranges approximately from below 0 to 1, with higher values indicating better health-related quality of life. Poor quality of life is defined a priori as an index value below 0.6.
Time frame: 7 days after ICU admission
Health-related Quality of Life
Health-related quality of life measured with the EQ-5D-5L. The EQ-5D-5L index value ranges approximately from below 0 to 1, with higher values indicating better health-related quality of life. Poor quality of life is defined a priori as an index value below 0.6.
Time frame: 28 days after ICU admission
Health-related Quality of Life
Health-related quality of life measured with the EQ-5D-5L. The EQ-5D-5L index value ranges approximately from below 0 to 1, with higher values indicating better health-related quality of life. Poor quality of life is defined a priori as an index value below 0.6.
Time frame: 3 months after ICU admission
6-Month Mortality
All-cause mortality within 6 months of ICU admission, ascertained from medical records or during structured follow-up contact. Includes deaths during the index hospitalisation and after discharge. Cause of death is recorded, including death following withdrawal or withholding of life-sustaining treatment.
Time frame: 6 months after ICU admission
Cognitive Function
Cognitive function assessed by the Telephone Montreal Cognitive Assessment (T-MoCA). Lower scores indicate greater cognitive impairment. Cognitive impairment is defined a priori as a T-MoCA score below 12.
Time frame: 6 months after ICU admission
Cognitive Function
Cognitive function assessed by the Telephone Montreal Cognitive Assessment (T-MoCA). Lower scores indicate greater cognitive impairment. Cognitive impairment is defined a priori as a T-MoCA score below 12.
Time frame: 3 months after ICU admission
Psychological Distress and Post-Traumatic Stress Symptoms
Post-traumatic stress symptoms assessed with the Impact of Event Scale-Revised (IES-R, range 0 to 88). Analysed as a continuous score; clinically significant post-traumatic stress is defined a priori as a score above 33.
Time frame: 6 months after ICU admission
Psychological Distress and Post-Traumatic Stress Symptoms
Post-traumatic stress symptoms assessed with the Impact of Event Scale-Revised (IES-R, range 0 to 88). Analysed as a continuous score; clinically significant post-traumatic stress is defined a priori as a score above 33.
Time frame: 3 months after ICU admission
Functional Status
Barthel Index recorded at ICU discharge and at day 28, from medical record review or telephone contact if the patient has already been discharged. Lower scores indicate greater functional dependency.
Time frame: 3 months after ICU admission
Functional Status
Barthel Index recorded at ICU discharge and at day 28, from medical record review or telephone contact if the patient has already been discharged. Lower scores indicate greater functional dependency.
Time frame: 6 months after ICU admission
Return to Work and Socioeconomic Recovery
Self-reported return to paid employment, whether family caregivers resumed work, whether the participant receives nursing support at home, and financial status (no difficulty, new difficulty, or same as before sepsis), recorded during structured telephone follow-up.
Time frame: 6 months after ICU admission
Return to Work and Socioeconomic Recovery
Self-reported return to paid employment, whether family caregivers resumed work, whether the participant receives nursing support at home, and financial status (no difficulty, new difficulty, or same as before sepsis), recorded during structured telephone follow-up.
Time frame: 3 months after ICU admission
Rehospitalization and Healthcare Utilization
Cumulative number and causes of rehospitalisations and outpatient consultations, collected through medical record review and participant self-report during the follow-up interview.
Time frame: 6 months after ICU admission
Decision regret regarding the ICU stay (Decision Regret Scale)
Regret regarding the ICU stay assessed with the five-item Decision Regret Scale, administered during structured telephone follow-up. Item responses are summed and linearly transformed to a total score ranging from 0 (no regret) to 100 (maximum regret); higher scores indicate greater regret. The continuous score is the registered outcome measure. For dichotomised analyses, moderate-to-strong regret is defined a priori as a score above 25, with a score of 0 indicating no regret and 1 to 25 indicating mild regret. Where a participating centre administers a validated language version with a different reported threshold, that threshold will be applied in pre-specified sensitivity analyses.
Time frame: 6 months after ICU admission
Freedom from renal replacement therapy
Percentage of participants who are alive and free from renal replacement therapy 6 months after ICU admission, among those who received renal replacement therapy for sepsis-associated acute kidney injury during the ICU stay. Freedom from renal replacement therapy is defined as no renal replacement therapy of any modality during the 30 days preceding the 6-month assessment, ascertained from medical record review and structured telephone follow-up. Participants who died before the 6-month assessment are counted as not having recovered renal function.
Time frame: 6 months after ICU admission
Physical health-related quality of life (Short Form-12 Physical Component Summary)
Physical Component Summary (PCS) score of the Short Form-12 Health Survey (SF-12), administered during structured telephone follow-up. The PCS is a norm-based score calibrated to a general-population mean of 50 and standard deviation of 10, ranging from 0 (worst physical health) to 100 (best physical health); higher scores indicate better physical health. The continuous score is the registered outcome measure. For dichotomised analyses, impaired physical health is defined a priori as a PCS score more than one standard deviation below the general-population norm (score below 40); where a country-specific general-population norm is available for a participating centre, that norm will be used in pre-specified sensitivity analyses.
Time frame: 3 months after ICU admission
Delirium during the ICU stay
Presence of delirium assessed with the CAM-ICU during the ICU stay, with duration of delirium and treatments administered.
Time frame: 6 months after ICU admission
Mental health-related quality of life (Short Form-12 Mental Component Summary)
Mental Component Summary (MCS) score of the Short Form-12 Health Survey (SF-12), administered during structured telephone follow-up. The MCS is a norm-based score calibrated to a general-population mean of 50 and standard deviation of 10, ranging from 0 (worst mental health) to 100 (best mental health); higher scores indicate better mental health. The continuous score is the registered outcome measure. For dichotomised analyses, impaired mental health is defined a priori as an MCS score more than one standard deviation below the general-population norm (score below 40); where a country-specific general-population norm is available for a participating centre, that norm will be used in pre-specified sensitivity analyses.
Time frame: 3 months after ICU admission
Mental health-related quality of life (Short Form-12 Mental Component Summary)
Mental Component Summary (MCS) score of the Short Form-12 Health Survey (SF-12), administered during structured telephone follow-up. The MCS is a norm-based score calibrated to a general-population mean of 50 and standard deviation of 10, ranging from 0 (worst mental health) to 100 (best mental health); higher scores indicate better mental health. The continuous score is the registered outcome measure. For dichotomised analyses, impaired mental health is defined a priori as an MCS score more than one standard deviation below the general-population norm (score below 40); where a country-specific general-population norm is available for a participating centre, that norm will be used in pre-specified sensitivity analyses.
Time frame: 6 months after ICU admission
Physical health-related quality of life (Short Form-12 Physical Component Summary)
Physical Component Summary (PCS) score of the Short Form-12 Health Survey (SF-12), administered during structured telephone follow-up. The PCS is a norm-based score calibrated to a general-population mean of 50 and standard deviation of 10, ranging from 0 (worst physical health) to 100 (best physical health); higher scores indicate better physical health. The continuous score is the registered outcome measure. For dichotomised analyses, impaired physical health is defined a priori as a PCS score more than one standard deviation below the general-population norm (score below 40); where a country-specific general-population norm is available for a participating centre, that norm will be used in pre-specified sensitivity analyses.
Time frame: 6 months after ICU admission
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Sep 2027, 12 months after the start.
Of 496 non-industry observational studies under Sepsis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 12 months is below that.
Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Geneva, Switzerland